Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis

Saad Alhumaid, Abbas Al Mutair, Zainab Al Alawi, Ali A Rabaan, Raghavendra Tirupathi, Mohammed A Alomari, Aqeel S Alshakhes, Abeer M Alshawi, Gasmelseed Y Ahmed, Hassan M Almusabeh, Tariq T Alghareeb, Abdulaziz A Alghuwainem, Zainab A Alsulaiman, Mohammed A Alabdulmuhsin, Emad A AlBuwaidi, Amjad K Bu Dukhi, Hani N Mufti, Manaf Al-Qahtani, Kuldeep Dhama, Jaffar A Al-Tawfiq, Awad Al-Omari, Saad Alhumaid, Abbas Al Mutair, Zainab Al Alawi, Ali A Rabaan, Raghavendra Tirupathi, Mohammed A Alomari, Aqeel S Alshakhes, Abeer M Alshawi, Gasmelseed Y Ahmed, Hassan M Almusabeh, Tariq T Alghareeb, Abdulaziz A Alghuwainem, Zainab A Alsulaiman, Mohammed A Alabdulmuhsin, Emad A AlBuwaidi, Amjad K Bu Dukhi, Hani N Mufti, Manaf Al-Qahtani, Kuldeep Dhama, Jaffar A Al-Tawfiq, Awad Al-Omari

Abstract

Background: Currently there is no systematic review and meta-analysis of the global incidence rates of anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines in the general adult population.

Objectives: To estimate the incidence rates of anaphylactic and nonanaphylactic reactions after COVID-19 vaccines and describe the demographic and clinical characteristics, triggers, presenting signs and symptoms, treatment and clinical course of confirmed cases.

Design: A systematic review and meta-analysis. Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] statement was followed.

Methods: Electronic databases (Proquest, Medline, Embase, Pubmed, CINAHL, Wiley online library, and Nature) were searched from 1 December 2020 to 31 May 2021 in the English language using the following keywords alone or in combination: anaphylaxis, non-anaphylaxis, anaphylactic reaction, nonanaphylactic reaction, anaphylactic/anaphylactoid shock, hypersensitivity, allergy reaction, allergic reaction, immunology reaction, immunologic reaction, angioedema, loss of consciousness, generalized erythema, urticaria, urticarial rash, cyanosis, grunting, stridor, tachypnoea, wheezing, tachycardia, abdominal pain, diarrhea, nausea, vomiting and tryptase. We included studies in adults of all ages in all healthcare settings. Effect sizes of prevalence were pooled with 95% confidence intervals (CIs). To minimize heterogeneity, we performed sub-group analyses.

Results: Of the 1,734 papers that were identified, 26 articles were included in the systematic review (8 case report, 5 cohort, 4 case series, 2 randomized controlled trial and 1 randomized cross-sectional studies) and 14 articles (1 cohort, 2 case series, 1 randomized controlled trial and 1 randomized cross-sectional studies) were included in meta-analysis. Studies involving 26,337,421 vaccine recipients [Pfizer-BioNTech (n = 14,505,399) and Moderna (n = 11,831,488)] were analyzed. The overall pooled prevalence estimate of anaphylaxis to both vaccines was 5.0 (95% CI 2.9 to 7.2, I2 = 81%, p = < 0.0001), while the overall pooled prevalence estimate of nonanaphylactic reactions to both vaccines was 53.9 (95% CI 0.0 to 116.1, I2 = 99%, p = < 0.0001). Vaccination with Pfizer-BioNTech resulted in higher anaphylactic reactions compared to Moderna (8.0, 95% CI 0.0 to 11.3, I2 = 85% versus 2.8, 95% CI 0.0 to 5.7, I2 = 59%). However, lower incidence of nonanaphylactic reactions was associated with Pfizer-BioNTech compared to Moderna (43.9, 95% CI 0.0 to 131.9, I2 = 99% versus 63.8, 95% CI 0.0 to 151.8, I2 = 98%). The funnel plots for possible publication bias for the pooled effect sizes to determine the incidence of anaphylaxis and nonanaphylactic reactions associated with mRNA COVID-19 immunization based on mRNA vaccine type appeared asymmetrical on visual inspection, and Egger's tests confirmed asymmetry by producing p values < 0.05. Across the included studies, the most commonly identified risk factors for anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines were female sex and personal history of atopy. The key triggers to anaphylactic and nonanaphylactic reactions identified in these studies included foods, medications, stinging insects or jellyfish, contrast media, cosmetics and detergents, household products, and latex. Previous history of anaphylaxis; and comorbidities such as asthma, allergic rhinitis, atopic and contact eczema/dermatitis and psoriasis and cholinergic urticaria were also found to be important.

Conclusion: The prevalence of COVID-19 mRNA vaccine-associated anaphylaxis is very low; and nonanaphylactic reactions occur at higher rate, however, cutaneous reactions are largely self-limited. Both anaphylactic and nonanaphylactic reactions should not discourage vaccination.

Keywords: Allergic; COVID-19; Immunologic; Incidence; Reactions; SARS-Cov-2; Systematic review; Vaccines.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Flow diagram of literature search and data extraction from of studies included in the systematic review and meta-analysis
Fig. 2
Fig. 2
Pooled estimate for the prevalence of anaphylaxis associated with mRNA COVID-19 immunization stratified by the vaccine type
Fig. 3
Fig. 3
Pooled estimate for the prevalence of nonanaphylactic reactions associated with mRNA COVID-19 immunization stratified by the vaccine type
Fig. 4
Fig. 4
Funnel plots to evaluate publication bias for the pooled effect size to determine the prevalence of anaphylaxis associated with mRNA COVID-19 immunization based on mRNA vaccine type
Fig. 5
Fig. 5
Funnel plots to evaluate publication bias for the pooled effect size to determine the prevalence of nonanaphylactic reactions associated with mRNA COVID-19 immunization based on mRNA vaccine type

References

    1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard 2021. . . Accessed 28 May 2021.
    1. United States Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccine 2021. . Accessed 6 Jun 2021.
    1. United States Food and Drug Administration. Moderna COVID-19 Vaccine 2021. . Accessed 6 Jun 2021.
    1. Temsah M-H, Barry M, Aljamaan F, Alhuzaimi AN, Al-Eyadhy A, Saddik B, Alsohime F, Alhaboob A, Alhasan K, Alaraj A. SARS-CoV-2 B. 1.1. 7 UK variant of concern lineage-related perceptions, COVID-19 vaccine acceptance and travel worry among healthcare workers. Front Public Health. 2021;9:617.
    1. Koritala T, Hussain A, Pleshkova Y, Dondapati L, Tirupathi R, Rabaan AA, Al Mutair A, Alhumaid11 S, Al-Tawfiq12 JA, Kashyap15 R. A narrative review of emergency use authorization versus full FDA approval and its effect on COVID-19 vaccination hesitancy.
    1. Dhama K, Sharun K, Tiwari R, Dhawan M, Emran TB, Rabaan AA, Alhumaid S. COVID-19 vaccine hesitancy–reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic. Hum Vaccin Immunother. 2021 doi: 10.1080/21645515.2021.1926183.
    1. American Academy of Allergy A, American College of Allergy A, Joint Council of Allergy A, Parameters JTFoP. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259–73.
    1. Lang DM, Patadia DD. Anaphylaxis to vaccinations: a review of the literature and evaluation of the COVID-19 mRNA vaccinations. Cleve Clin J Med. 2021 doi: 10.3949/ccjm.88a.ccc075.
    1. Schnyder B, Pichler WJ. Mechanisms of drug-induced allergy. Mayo Clin Proc. 2009 doi: 10.4065/84.3.268.
    1. Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990–2016. J Allergy Clin Immunol. 2019;143(4):1465–1473. doi: 10.1016/j.jaci.2018.12.1003.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.
    1. Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011.
    1. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 doi: 10.1136/bmj.l4898.
    1. Schmidt FL, Hunter JE. Meta-analysis. In: Weiner IB, editor. Handbook of psychology. Hoboke: John Wiley & Sons Inc; 2003. pp. 533–554.
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi: 10.1002/sim.1186.
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557.
    1. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi: 10.1136/bmj.315.7109.629.
    1. Ackerman M, Henry D, Finon A, Binois R, Esteve E. Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021 doi: 10.1111/jdv.17248.
    1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi: 10.1056/NEJMoa2035389.
    1. Bae S, Lee YW, Lim SY, Lee J-H, Lim JS, Lee S, Park S, Kim S-K, Lim Y-J, Kim EO. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci. 2021 doi: 10.3346/jkms.2021.36.e115.
    1. Bianchi L, Biondi F, Hansel K, Murgia N, Tramontana M, Stingeni L. Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: limits of intradermal testing. Allergy. 2021 doi: 10.1111/all.14839.
    1. Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, Hashimoto D, Banerji A, Li L, Anvari S. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med. 2021;384(13):1273–1277. doi: 10.1056/NEJMc2102131.
    1. Corbeddu M, Diociaiuti A, Vinci M, Santoro A, Camisa V, Zaffina S, El Hachem M. Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single centre case series. J Eur Acad Dermatol Venereol. 2021 doi: 10.1111/jdv.17268.
    1. Covid C, Team R Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14–23, 2020. Morb Mortal Wkly Rep. 2021;70(2):46. doi: 10.15585/mmwr.mm7002e1.
    1. Frank A, Radparvar S, Manasia A, Bassily-Marcus A, Kohli-Seth R. Prolonged anaphylaxis to pfizer coronavirus disease 2019 vaccine: a case report and mechanism of action. Crit Care Explor. 2021 doi: 10.1097/CCE.0000000000000397.
    1. Johnston MS, Galan A, Watsky KL, Little AJ. Delayed localized hypersensitivity reactions to the moderna COVID-19 vaccine: a case series. JAMA Dermatol. 2021 doi: 10.1001/jamadermatol.2021.1214.
    1. Kadali RAK, Janagama R, Peruru S, Gajula V, Madathala RR, Chennaiahgari N, Malayala SV. Adverse effects of COVID-19 mRNA-1273 vaccine: a randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol. 2021 doi: 10.1002/jmv.26996.
    1. Kelso JM. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines. Ann Allergy Asthma Immunol. 2021 doi: 10.1016/j.anai.2021.03.024.
    1. Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, Petrakis D, Bakerly ND. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. Life. 2021;11(3):249. doi: 10.3390/life11030249.
    1. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, Desai SR, French LE, Lim HW, Thiers BH. Cutaneous reactions reported after moderna and pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021 doi: 10.1016/j.jaad.2021.03.092.
    1. Mustafa SS, Ramsey A, Staicu ML. Administration of a second dose of the moderna COVID-19 vaccine after an immediate hypersensitivity reaction with the first dose: two case reports. Ann Intern Med. 2021 doi: 10.7326/L21-0104.
    1. Ocáriz M, Zubeldia Ortuño J. Safety of new MRNA vaccines against COVID-19 in severe allergic patients. J Investig Allergol Clin Immunol. 2021 doi: 10.18176/jiaci.0683.
    1. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Reports of events managed as anaphylaxis following COVID-19 vaccines in Ontario: December 13, 2020 to March 6, 2021 2021. . Accessed 29 May 2021.
    1. Park LHJ, Montgomery CJR, Boggs LNA. Anaphylaxis after the Covid-19 vaccine in a patient with cholinergic urticaria. Mil Med. 2021 doi: 10.1093/milmed/usab138.
    1. Pitlick MM, Sitek AN, Kinate SA, Joshi AY, Park MA. Polyethylene glycol and polysorbate skin testing in the evaluation of COVID-19 vaccine reactions: early report. Ann Allergy Asthma Immunol. 2021 doi: 10.1016/j.anai.2021.03.012.
    1. Restivo V, Candore G, Barrale M, Caravello E, Graziano G, Onida R, Raineri M, Tiralongo S, Brusca I. Allergy to polyethilenglicole of anti-SARS CoV2 vaccine recipient: a case report of young adult recipient and the management of future exposure to SARS-CoV2. Vaccines. 2021;9(5):412. doi: 10.3390/vaccines9050412.
    1. Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J Clin Med. 2021;10(7):1428. doi: 10.3390/jcm10071428.
    1. Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin Exp Allergy. 2021 doi: 10.1111/cea.13874.
    1. Shimabukuro T. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine—United States, December 21, 2020–January 10, 2021. Am J Transplant. 2021;21(3):1326. doi: 10.1111/ajt.16517.
    1. Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 2021;325(8):780–781. doi: 10.1001/jama.2021.0600.
    1. Vieira J, Marcelino J, Ferreira F, Farinha S, Silva R, Proença M, Tomaz E. Skin testing with Pfizer SARS-CoV-2 vaccine and PEG 2000. Asia Pac Allergy. 2021 doi: 10.5415/apallergy.2021.11.e18.
    1. Rüggeberg JU, Gold MS, Bayas J-M, Blum MD, Bonhoeffer J, Friedlander S, de Souza BG, Heininger U, Imoukhuede B, Khamesipour A. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5675–5684. doi: 10.1016/j.vaccine.2007.02.064.
    1. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF, Jr, Bock SA, Branum A, Brown SG, Camargo CA, Jr, Cydulka R, Galli SJ. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Journal of Allergy and Clinical Immunology. 2006;117(2):391–397. doi: 10.1016/j.jaci.2005.12.1303.
    1. Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med. 2021;384(7):643–649. doi: 10.1056/NEJMra2035343.
    1. Somiya M, Mine S, Yasukawa K, Ikeda S. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines. Vaccine. 2021 doi: 10.1016/j.vaccine.2021.04.066.
    1. Rutkowski K, Mirakian R, Till S, Rutkowski R, Wagner A. Adverse reactions to COVID-19 vaccines: a practical approach. Clin Exp Allergy. 2021 doi: 10.1111/cea.13880.
    1. Dages KN, Pitlick MM, Joshi AY, Park MA. Risk of allergic reaction in patients with atopic disease and recent COVID-19 vaccination. Ann Allergy Asthma Immunol. 2021 doi: 10.1016/j.anai.2021.04.024.
    1. Krantz MS, Bruusgaard-Mouritsen MA, Koo G, Phillips EJ, Stone CA, Jr, Garvey LH. Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don’t give up on the second dose. Allergy. 2021 doi: 10.1111/all.14958.
    1. Vander Leek TK, Chan ES, Connors L, Derfalvi B, Ellis AK, Upton JE, Abrams EM. COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI) Allergy Asthma Clin Immunol. 2021;17(1):1–6. doi: 10.1186/s13223-021-00529-2.
    1. Panesar SS, Nwaru BI, Hickstein L, Rader T, Hamadah H, Ali DFI, Patel B, Muraro A, Roberts G, Worm M. The epidemiology of anaphylaxis in Europe: protocol for a systematic review. Clin Transl Allergy . 2013;3(1):1–5. doi: 10.1186/2045-7022-3-9.
    1. Canadian Society of Allergy and Clinical Immunology (CSACI). SARS-CoV-2 vaccine testing & administration guidance for allergists/immunologists from the CSACI 2021. . Accessed 26 Sep 2021.
    1. Gold MS, MacDonald NE, McMurtry CM, Balakrishnan MR, Heininger U, Menning L, Benes O, Pless R, Zuber PL. Immunization stress-related response–redefining immunization anxiety-related reaction as an adverse event following immunization. Vaccine. 2020;38(14):3015–3020. doi: 10.1016/j.vaccine.2020.02.046.
    1. Altrichter S, Salow J, Ardelean E, Church MK, Werner A, Maurer M. Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria. J Dermatol Sci. 2014;75(2):88–93. doi: 10.1016/j.jdermsci.2014.04.007.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere